Special series on platelet transfusion

Platelet transfusion is a common practice in hospitalized patients for preventing or treating hemorrhages. More than 50% of platelets are transfused to patients diagnosed of onco-hematological diseases receiving chemotherapy and/or hematopoietic stem cell transplantation (1-3). With the aim to help physicians to take the most accurate decisions on platelet transfusion, some guidelines have been developed based on the scarcely available scientific evidence (4-8). However, there are some controversial issues and available scientific evidence is still not enough to solve most of them. There is little evidence about which is the best platelet product to be transfused: random platelets or single donor apheresis platelets, and plasma-suspended or additive solution-suspended platelets. The pathogen reduction technologies (PRT) have been implemented in some countries order to reduce the infectious complications related to blood component transfusion. However, the effects of PRT on the in vivo transfused platelet effects are not clearly established. The clinical use of cryopreserved platelets is not well defined since the effect of cryopreservation on platelet function is debated. Platelet transfusion refractoriness (PTR) is a challenging complication raised from multiple platelet transfusions. The detection and management of this complication is often disappointing (9-11). In summary, although it is a widespread practice, platelet transfusion has still some controversial and unknown aspects. The objective of this supplement is to update the current evidence and provide information on some specific platelet transfusion issues.

In the first chapter, Ren and colleagues (12) review and update the leading causes of immunologic platelet transfusion refractoriness (PTR) in patients with acute leukemia. PTR is an important problem in clinical practice for patients with hematological malignancies with high platelet transfusion requirements. This condition produces inefficiency of platelet transfusions, and significantly increases the risk of life-threatening bleeding. The development of alloantibodies against HLA and less frequently against human platelet antigens produces immune destruction of transfused platelets. Alloantibodies against CD36 (platelet glycoprotein 4), developed in type I CD36-deficient patients have been reported to cause immune platelet destruction. Authors explain the different approaches to prevent and overcome immune PTR.

In the following chapter Dr Jiménez-Marco (13) explains The Balearic Islands Blood Bank (BIBB) experience on use of pathogen reduction technologies (PRT). BIBB implemented the pathogen reduction technology in 2008 and is one of the few blood establishments worldwide with more than 10 years of routine use of two different PRT systems currently available for platelet concentrates: Intercept and Mirasol. Dr Jimenez Marco discuss the main advantages but also the limitations of different PRT. Some advantages are the reduction/elimination of septic reactions and the extension of platelet shelf-life to 7 days, without a significant impact on platelet functionality. On the contrary, the costs of procedure and the resistance of some virus to the inactivation are the main limitations. In addition, PRT has the potential to reasonable guarantee blood safety in situations of epidemics and pandemics.

In the third chapter, Dr. Ness and colleague (14) discuss the potential advantages of single donor platelets (SDP) as compared to Whole blood derived platelets (WDP). Most of the potential advantages of SDP have remained unproven with time. The reduction of septic platelet transfusion reactions has been considered the most important advantage. Since the bacterial testing or pathogen inactivation techniques have been implemented for platelet products, this advantage has become less relevant. In general, SDP are preferred for hematologic patients and for those who develop immune platelet transfusion refractoriness, and need cross matched or HLA matched platelets that can only be obtained from SPD. A combined inventory of SPD and WDP appeared to be the best approach.

Next, Dr Lozano and colleague (15) summarize the role of cryopreserved platelets in transfusion therapy and review the effects of cryopreservation on structure and function of thawed platelets. Different methods for platelet cryopreservation have been described over the time. Dr Lozano has collected information from the literature and from his own experience about impact of freezing and thawing on platelet function. An increase in platelet procoagulant activity has been associated to the platelet freezing and thawing. Possibly for these reasons among others, in the real life use of cryopreserved platelets is limited to specific clinical scenarios where conventional platelets are not available as for patients with HLA/HPA alloimmunization and military operations.

In the following chapter, Dr Hagino (16) focuses on the major causes of non-immune platelet transfusion refractoriness (PTR) that is two times more frequent than immune PTR. Several conditions as fever/sepsis, splenomegaly, bleeding,
hematopoietic stem cell transplantation and drugs can produce a shortening in platelet survival. Authors consider that appropriate management of this adverse condition consists of different steps that include an accurate indication of platelet transfusion, an investigation of causes, consideration of the coexistence of immune and non-immune PTR and a selection of treatment adapted to each specific cause.

In the last chapter (17), Dr. Sato and colleagues provide interesting data about platelet transfusion practice in Japan. In fact, the situation of platelet transfusion in Japan is quite different to other developed countries, since all platelets transfused are single-donor apheresis (SDP). Because of pathogen reduction technologies are not implemented, the platelet shelf-life is limited to three days in order to mitigate the transfusion-transmitted bacterial infection risk. Data available in Japan regarding the adverse effects of transfusion are provided by two different hemovigilance systems: the Japanese Red Cross Society and National institute of Infectious Diseases of Japan together with the Hemovigilance Committee of the Japan Society of Transfusion Medicine and Cell Therapy. Despite evident differences, adverse effects recorded are similar to those reported by other hemovigilance systems outside Japan. Allergic reactions were the most frequent adverse effect and occurred in 35.86 per 100,000 platelet bags followed by non-hemolytic fever reactions. Authors also provide useful information about management of different adverse effects.

In summary, the series on platelet transfusion provides sensible information about critical aspects of platelet transfusion. We believe that the content of this series will be useful in clinical practice for management of patients with platelet transfusion requirements.

**Acknowledgments**

**Funding:** None.

**Footnote**

**Provenance and Peer Review:** This article was commissioned by the editorial office, *Annals of Blood* for the series “Platelet Transfusion”. The article did not undergo external peer review.

**Conflicts of Interest:** The author has completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/aob-2021-04). The series “Platelet Transfusion” was commissioned by the editorial office without any funding or sponsorship. Pilar Solves served as an unpaid Guest Editor of the series and serves as an unpaid editorial board member of *Annals of Blood* from April 2020 to April 2022. The author has no other conflicts of interest to declare.

**Ethical Statement:** The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

**References**


Pilar Solves Alcaina

Pilar Solves Alcaina1,2, MD, PhD
1Blood Bank, Hematology Unit, Hospital Universitari I Politècnic La Fe, Valencia, Spain; 2CIBERONC, Instituto Carlos III, Madrid, Spain. (Email: solves_pil@gva.es)

Received: 05 December 2021. Accepted: 17 December 2021.
doi: 10.21037/aob-2021-04

View this article at: https://dx.doi.org/10.21037/aob-2021-04

Cite this article as: Solves Alcaina P. Special series on platelet transfusion. Ann Blood 2021.

doi: 10.21037/aob-2021-04